COMMITTED TO DEVELOPING TARGETED TREATMENTS FOR
DIFFICULT TO TREAT ADVANCED CANCERS
AlonBio is an oncology biotechnology company focused on discovering and developing targeted cancer therapies. We identify and target key drivers of cancer cell growth, resistance, and survival.
Our core competencies in cancer biology research and drug development, taken together with our small molecule screening platforms enable a rapid translation of our discoveries into potential treatments for difficult-to-treat aggressive cancers.
Our lead asset BKT300 is a novel, first-in-class, highly selective, PRC1 inhibitor developed as a targeted anti-cancer treatment.
We have assembled an experienced management team with deep expertise in oncology research and drug development. and a demonstrated track record of success building biotech companies and developing novel therapeutics.
BOARD OF DIRECTORS
H. Laurence Shaw, M.D.
Prof. Amnon Peled, Ph.D.
Chief Scientific Officer
Shmuel Cabilly, Ph.D.
Arnon Aharon, M.D.
Chief Executive Officer
Anthony Trevor Stanton